Post hoc longitudinal assessment of efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B.
Sign Up to like & getrecommendations! Published in 2023 at "Blood advances"
DOI: 10.1182/bloodadvances.2022009230
Abstract: Long-term efficacy and safety of the extended half-life recombinant FIX Fc fusion protein (rFIXFc) has been established in previously treated patients with severe hemophilia B in 2 Phase 3 trials (B-LONG [NCT01027364] and Kids B-LONG… read more here.
Keywords: every days; fusion protein; efficacy safety; kids long ... See more keywords